# Fumihiro Takahashi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/fumihiro-takahashi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,161 |
| Field | Amyotrophic Lateral Sclerosis Research |
| h-index | 9 |
| i10-index | 9 |
| Last Known Institution | Mitsubishi Group (Japan) |
| OpenAlex ID | https://openalex.org/A5050956962 |
| ORCID iD | 0000-0001-5701-5332 |
| Works | 35 |

## Researcher papers

- [Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/safety-and-efficacy-of-edaravone-in-well-defined-patients-with-amyotrophic/)
- [Regulation of cell-cell contacts in developing Drosophila eyes by Dsrc41, a new, close relative of vertebrate c-src.](https://scholariq.org/papers/regulation-of-cell-cell-contacts-in-developing-drosophila-eyes-by-dsrc41-a-new/)
- [An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe](https://scholariq.org/papers/an-assessment-of-treatment-guidelines-clinical-practices-demographics-and/)
- [Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis](https://scholariq.org/papers/post-hoc-analysis-of-mci186-17-the-extension-study-to-mci186-16-the-confirmatory/)
- [Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis](https://scholariq.org/papers/post-hoc-analysis-of-randomised-placebo-controlled-double-blind-study-mci186-19/)
- [Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis](https://scholariq.org/papers/post-hoc-analysis-of-open-label-extension-period-of-study-mci186-19-in/)
- [Erythropoietic Protoporphyria: Phase 2 Clinical Trial Results Evaluating the Safety and Effectiveness of Dersimelagon (MT-7117), an Oral MC1R Agonist](https://scholariq.org/papers/erythropoietic-protoporphyria-phase-2-clinical-trial-results-evaluating-the/)
- [Bayesian noninferiority test for 2 binomial probabilities as the extension of Fisher exact test](https://scholariq.org/papers/bayesian-noninferiority-test-for-2-binomial-probabilities-as-the-extension-of/)
- [The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis](https://scholariq.org/papers/the-effects-of-intervention-with-intravenous-edaravone-in-study-19-on/)
- [Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of <scp>ALSFRS‐R</scp> item scores in pivotal study <scp>MCI186</scp>‐19](https://scholariq.org/papers/slowing-the-loss-of-physical-function-in-amyotrophic-lateral-sclerosis-with/)

## Researcher topics

- [Amyotrophic Lateral Sclerosis Research](https://scholariq.org/topics/amyotrophic-lateral-sclerosis-research/)
- [Genetic Neurodegenerative Diseases](https://scholariq.org/topics/genetic-neurodegenerative-diseases/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Parkinson's Disease and Spinal Disorders](https://scholariq.org/topics/parkinson-s-disease-and-spinal-disorders/)
- [Parkinson's Disease Mechanisms and Treatments](https://scholariq.org/topics/parkinson-s-disease-mechanisms-and-treatments/)

## Researcher university

- [Mitsubishi Group (Japan)](https://scholariq.org/institutions/mitsubishi-group-japan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.